Custom-Made vaccine fights deadly brain tumor
NCT ID NCT02287428
Summary
This early-stage study is testing a new, personalized cancer vaccine for people newly diagnosed with glioblastoma, a fast-growing brain tumor. The vaccine is custom-made for each patient using proteins from their own tumor, with the goal of training their immune system to attack remaining cancer cells. Participants receive the vaccine along with standard radiation and, for most, an immunotherapy drug called pembrolizumab for up to two years to help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02113, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.